Phase 3 Narcolepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have already been eligible for and completed the end-of-treatment visit in one of the qualifying earlier studies of ALKS 2680 (called Vibrance-1, Vibrance-2, or Vibrance-3) for narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia.
- You must be willing and able to safely stop taking any medications you currently use to manage your sleep disorder symptoms, at least 5 half-lives before the study starts (if you are re-joining) and for the entire length of the study — your doctor must also agree this is safe for you.
Who may not be able to join:
- You may not be able to join if you have developed a new significant health problem, or have new abnormal heart or lab test results since the earlier study, which the study doctor believes could affect your ability to safely participate.
- You cannot join if you are currently pregnant, breastfeeding, or planning to become pregnant during the study.
- You cannot join if you are currently taking part in another clinical trial (other than the qualifying earlier study), or if you have taken an experimental drug or used an experimental device within the last 30 days before screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Alkermes, Inc.
Phone: 888-235-8008 (US Only)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Treatment-Emergent Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.